Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease.
Nisha B ShahAutumn D ZuckermanKatie R HostengJessica FannJosh DeClercqLeena ChoiLaura CherryDavid A SchwartzSara HorstPublished in: Digestive diseases and sciences (2023)
Patients who had a longer time to insurance approval were less likely to have improvement in CRP, highlighting the negative clinical impact of a complex dose escalation process.
Keyphrases
- disease activity
- rheumatoid arthritis
- patients with inflammatory bowel disease
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- open label
- health insurance
- affordable care act
- juvenile idiopathic arthritis
- drug administration
- long term care
- mesenchymal stem cells
- clinical trial
- randomized controlled trial
- bone marrow